These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 30728962)
21. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. Foolad F; Taylor BD; Shelburne SA; Arias CA; Aitken SL J Antimicrob Chemother; 2018 Sep; 73(9):2277-2283. PubMed ID: 29547977 [TBL] [Abstract][Full Text] [Related]
22. Evaluating the impact of obesity on safety and efficacy of weight-based norepinephrine dosing in septic shock: A single-center, retrospective study. Wong PJ; Pandya KA; Flannery AH Intensive Crit Care Nurs; 2017 Aug; 41():104-108. PubMed ID: 28343834 [TBL] [Abstract][Full Text] [Related]
23. Characterization of plasma daptomycin in patients with serum highly glycated albumin and obesity. Miyadera Y; Yamada T; Imoto Y; Yagi T; Naito T; Kawakami J J Infect Chemother; 2023 Feb; 29(2):119-125. PubMed ID: 36216220 [TBL] [Abstract][Full Text] [Related]
25. Review of current evidence available for guiding optimal Enoxaparin prophylactic dosing strategies in obese patients-Actual Weight-based vs Fixed. He Z; Morrissey H; Ball P Crit Rev Oncol Hematol; 2017 May; 113():191-194. PubMed ID: 28427508 [TBL] [Abstract][Full Text] [Related]
26. Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Moenster RP; Linneman TW; Finnegan PM; McDonald JR Clin Ther; 2012 Jul; 34(7):1521-7. PubMed ID: 22748973 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of a standardized daptomycin dosing nomogram. Schmidt S; Sloan A; Maxwell A; Swindler J Am J Health Syst Pharm; 2016 Sep; 73(17 Suppl 4):S106-11. PubMed ID: 27543595 [TBL] [Abstract][Full Text] [Related]
28. Decreasing the probability of creatine phosphokinase elevations: clinical considerations for daptomycin dosing in obese patients. Donovan BJ; Mohr JF; Knapp AG; Eisenstein BI Clin Infect Dis; 2010 Oct; 51(8):989; author reply 989-90. PubMed ID: 20858080 [No Abstract] [Full Text] [Related]
29. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889 [TBL] [Abstract][Full Text] [Related]
30. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467 [TBL] [Abstract][Full Text] [Related]
31. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Falcone M; Russo A; Venditti M; Novelli A; Pai MP Clin Infect Dis; 2013 Dec; 57(11):1568-76. PubMed ID: 24046298 [TBL] [Abstract][Full Text] [Related]
32. Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia. Timbrook TT; Caffrey AR; Luther MK; Lopes V; LaPlante KL Pharmacotherapy; 2018 Feb; 38(2):189-196. PubMed ID: 29235661 [TBL] [Abstract][Full Text] [Related]
33. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569 [TBL] [Abstract][Full Text] [Related]
34. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding. Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443 [TBL] [Abstract][Full Text] [Related]
35. Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review. Thimotheo Batista JP; Santos Marzano LA; Menezes Silva RA; de Sá Rodrigues KE; Simões E Silva AC Curr Med Chem; 2023; 30(9):1003-1028. PubMed ID: 35946096 [TBL] [Abstract][Full Text] [Related]
36. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. Pai MP; Mercier RC; Allen SE Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations. Bhavnani SM; Ambrose PG; Hammel JP; Rubino CM; Drusano GL Antimicrob Agents Chemother; 2015 Dec; 60(3):1600-7. PubMed ID: 26711755 [TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. Dvorchik BH; Damphousse D J Clin Pharmacol; 2005 Jan; 45(1):48-56. PubMed ID: 15601805 [TBL] [Abstract][Full Text] [Related]
39. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Feagan BG; Macdonald JK Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890 [TBL] [Abstract][Full Text] [Related]
40. A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase. Lehman B; Neuner EA; Heh V; Isada C Open Forum Infect Dis; 2019 Nov; 6(11):ofz444. PubMed ID: 31723571 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]